![making crack with levamisole hydrochloride making crack with levamisole hydrochloride](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00204-017-1947-4/MediaObjects/204_2017_1947_Fig5_HTML.gif)
Musculoskeletal side effects including arthralgia (5%) and myalgia (3%) have been reported. CardiovascularĬardiac dysfunction leading to edema (1%) and chest pain (<1%) have been reported. Flatulence and dyspepsia have also been reported. Gastrointestinal side effects include nausea (22%), diarrhea (13%), vomiting (6%), stomatitis (3%), anorexia (2%), abdominal pain (2%), and constipation (2%). įlu-like symptoms including fatigue (6%), fever (3%), rigors (3%), myalgia, and malaise have been reported. Otherįever may be a symptom of infection associated with agranulocytosis, but often it is not. ĭermatologic side effects include dermatitis (8%), alopecia (3%), pruritus (1%) and urticaria (<1%).
Making crack with levamisole hydrochloride skin#
Half of the patients experiencing skin rash discontinued therapy (7%). One analysis of 267 reports representing 6,217 patients, found that patients treated for rheumatic disorders (n=1131) reported a significantly high percentage of idiosyncratic or allergic reactions. Agranulocytosis is spontaneously reversible when treatment is discontinued. Management of levamisole-induced agranulocytosis includes early diagnosis, discontinuation of treatment, and prevention of infection. Reports show some indication that agranulocytosis is due to a type II reaction (Coombs' classification). Leukopenia is usually not prodromal to agranulocytosis. The majority of these patients (4.5%) discontinued therapy. One analysis of 267 reports representing 6,217 patients, found that patients treated for rheumatic disorders (n=1131) reported a significantly higher rate of leukopenia and agranulocytosis (4.9%). In patients with thrombocytopenia, 1% of patients show platelet counts over 130,000/mm3, and 1% show platelet counts between 50,000 and 130,000/mm3. Transient granulocytopenia has been reported in up to 20% of treated patients. Hematologic toxicity primarily involves (sometimes fatal) agranulocytosis. Applies to levamisole: oral tablet Hematologic